LEI 5493002P3RCOFW6HI207
Novakand Pharma AB
Contract awards & public grants
Targeting neuroinflammation to combat pathological pain in neurodegenerative diseases and chronic pain syndromes → KANCERA AB
European Commission · SE · Grant · 2018-07-05
€263,659
Targeting SYNthetic lethal interactions for new cancer treatments TRAINing network → KANCERA AB
European Commission · SE · Grant · 2016-08-10
€527,319
Entity identity is matched from published recipient names and registry IDs to GLEIF legal-entity records; matches can be imperfect. Source records are public procurement and grant notices.